BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38425989)

  • 21. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
    Nuzzo G; Giuliante F; Ardito F; Vellone M; Pozzo C; Cassano A; Giovannini I; Barone C
    J Gastrointest Surg; 2007 Mar; 11(3):318-24. PubMed ID: 17458605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.
    Peng J; Liu Y; Li W; Lin Y; Sun H; Pan Z; Wu X; Fan W; Lin J
    Therap Adv Gastroenterol; 2021; 14():17562848211066206. PubMed ID: 34987612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection.
    Deng Y; Zhao Y; Qin J; Huang X; Wu R; Zhou C; Pan Z
    Pathol Oncol Res; 2021; 27():633480. PubMed ID: 34257601
    [No Abstract]   [Full Text] [Related]  

  • 24. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis.
    Takamizawa Y; Inoue M; Moritani K; Tsukamoto S; Esaki M; Shimada K; Kanemitsu Y
    Langenbecks Arch Surg; 2022 Nov; 407(7):2893-2903. PubMed ID: 36068379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
    Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
    Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated tumor-to-liver uptake ratio (TLR) from
    Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.
    Wang J; Huang A; Wang YP; Yin Y; Fu PY; Zhang X; Zhou J
    Ann Transl Med; 2020 Mar; 8(5):237. PubMed ID: 32309384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.
    Yuan SQ; Nie RC; Huang YS; Chen YB; Wang SY; Sun XW; Li YF; Liu ZK; Chen YX; Yao YC; Xu Y; Qiu HB; Liang Y; Wang W; Liu ZX; Zhao Q; Xu RH; Zhou ZW; Wang F
    Cancer Commun (Lond); 2023 Dec; 43(12):1312-1325. PubMed ID: 37837629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
    Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
    Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
    Mima K; Beppu T; Chikamoto A; Miyamoto Y; Nakagawa S; Kuroki H; Okabe H; Hayashi H; Sakamoto Y; Watanabe M; Kikuchi K; Baba H
    Int J Clin Oncol; 2013 Oct; 18(5):847-55. PubMed ID: 22940848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer.
    Watanabe A; Araki K; Harimoto N; Kubo N; Igarashi T; Ishii N; Yamanaka T; Hagiwara K; Kuwano H; Shirabe K
    Int J Clin Oncol; 2018 Aug; 23(4):689-697. PubMed ID: 29574651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative circulating tumor DNA testing based on tumor naïve strategy after liver metastasis surgery in colorectal cancer patients.
    Jiang H; Huang F; Yang Y; Chen X; Shen M; Zhang C; Pan B; Wang B; Guo W
    Front Oncol; 2023; 13():1153685. PubMed ID: 37213289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
    Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
    He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
    Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
    Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
    Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
    Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
    Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.